11
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

Cell Therapy, Advanced Materials, and New Approaches to Acute Kidney Injury

, MD & , MD
Pages 137-143 | Published online: 24 Jun 2015

References

  • Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P; Acute Dialysis Quality Initiative Workgroup. Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004; 8(4):R204–R212.
  • Bell M, Liljestam E, Granath F, Fryckstedt J, Ekbom A, Martling CR. Optimal follow-up time after continuous renal replacement therapy in actual renal failure patients stratified with the RIFLE criteria. Nephrol Dial Transplant. 2005; 20(2):354–360.
  • Kuitunen A, Vento A, Suojaranta-Ylinen R, Pettilä V. Acute renal failure after cardiac surgery: evaluation of the RIFLE classification. Ann Thorac Surg. 2006; 81 (2):542–546.
  • Uchino S, Bellomo R, Goldsmith D, Bates S, Ronco C. An assessment of the RIFLE criteria for acute renal failure in hospitalized patients. Crit Care Med. 2006; 34(7): 1913–1917.
  • Waikar SS, Curhan GC, Wald R, McCarthy EP, Chertow GM. Declining mortality in patients with acute renal failure, 1988 to 2002. J Am Soc Nephrol. 2006; 17(4): 1143–1150.
  • Xue JL, Daniels F, Star RA, et al. Incidence and mortality of acute renal failure in Medicare beneficiaries, 1991 to 2002. J Am Soc Nephrol. 2006; 17(4): 1135–1142.
  • Uchino S, Kellum JA, Bellomo R, et al; Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators: Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005; 294(7):813–818.
  • Mehta RL, Pascual MT, Soroko S, et al; Program to Improve Care in Acute Renal Disease. Spectrum of acute renal failure in the intensive care unit: the PICARD experience. Kidney Int. 2004; 66(4): 1613–1621.
  • Lu CY, Hartono J, Senitko M, Chen J. The inflammatory response to ischemic acute kidney injury: a result of the 'right stuff in the ‘wrong place’? Curr Opin Nephrol Hypertens. 2007; 16(2):83–89.
  • Bouman CS, Oudemans-Van Straaten HM, Tijssen JG, Zandstra DF, Kesecioglu J. Effects of early high-volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. Crit Care Med. 2002; 30(10):2205–2211.
  • Bauer M, Marzi I, Ziegenfuss T, Riegel W. Prophylactic hemofiltration in severely traumatized patients: effects on post-traumatic organ dysfunction syndrome. Intensive Care Med. 2001; 27(2):376–383.
  • John S, Eckardt KU. Renal replacement therapy in the treatment of acute renal failure-intermittent and continuous. Semin Dial. 2006; 19(6): 455–464.
  • Hakim RM, Wingard RL, Parker RA. Effect of the dialysis membrane in the treatment of patients with acute renal failure. N Engl J Med. 1994; 331(20): 1338–1342.
  • Schiffl H, Lang SM, König A, Strasscr T, Haider MC, Held E. Biocompatible membranes in acute renal failure: prospective case-controlled study. Lancet. 1994; 344(8922):570–572.
  • Modi GK, Pereira BJ, Jaber BL. Hemodialysis in acute renal failure: does the membrane matter? Semin Dial. 2001; 14(5):318–321.
  • Stadnyk AW. Cytokine production by epithelial cells. FASEBJ. 1994; 8(13): 1041–1047.
  • Deneke SM, Fanburg BL. Regulation of cellular glutathione. Am J Physiol. 1989; 257(4 pt 1):L163–L173.
  • Tannen RL, Sastrasinh S. Response of ammonia metabolism to acute acidosis. Kidney Int. 1984; 25(1):1–10.
  • Maack T. Renal handling of proteins and polypeptides. In: Windhager EE, ed. Handbook of Physiology. New York, NY: Oxford University Press; 1992: 2039–2118.
  • Bishop GA, Waugh JA, Hall BM. Expression of HLA antigens on renal tubular cells in culture. II. Effect of increased HLA antigen expression on tubular cell stimulation of lymphocyte activation and on their vulnerability to cell-mediated lysis. Transplantation. 1988; 46(2): 303–310.
  • Wahl P, Schoop R, Bilie G, et al. Renal tubular epithelial expression of the costimulatory molecule B7RP-1 (inducible costimulator ligand). J Am Soc Nephrol. 2002; 13(6): 1517–1526.
  • Prodjosudjadi W, Gerritsma JS, Klar-Mohamad N, et al. Production and cytokine-mediated regulation of monocyte chemoattractant protein-1 by human proximal tubular epithelial cells. Kidney Int. 1995; 48(5): 1477–1486.
  • Humes HD. Bioartificial kidney for full renal replacement therapy. Semin Nephrol. 2000; 20(1):71–82.
  • Humes HD, Fissell WH, Weitzel WF. The bioartificial kidney in the treatment of acute renal failure. Kidney Int Suppl. 2002; (80):S121–S125.
  • Humes HD, Buffington DA, MacKay SM, Funke AJ, Weitzel WF. Replacement of renal function in uremic animals with a tissue- engineered kidney. Nat Biotechnol. 1999; 17(5):451–455.
  • Humes HD, Fissell WH, Weitzel WF, et al. Metabolie replacement of kidney function in uremic animals with a bioartificial kidney containing human cells. Am J Kidney Dis. 2002; 39(5): 1078–1087.
  • Fissell WH, Dyke DB, Weitzel WF, et al. Bioartificial kidney alters cytokine response and hemodynamics in endotoxin-challenged uremic animals. Blood Purif 2002; 20(1):55–60.
  • Fissell WH, Lou L, Abrishami S, Buffington DA, Humes HD. Bioartificial kidney ameliorates gram-negative bacteria-induced septic shock in uremic animals. J Am Soc Nephrol. 2003; 14(2):454–461.
  • Humes HD, Buffington DA, Lou L, et al. Cell therapy with a tissue-engineered kidney reduces the multiple-organ consequences of septic shock. Crit Care Med. 2003; 31(10): 2421–2428.
  • Humes HD, Weitzel WF, Bartlett RH, et al. Initial clinical results of the bioartificial kidney containing human cells in ICU patients with acute renal failure. Kidney Int. 2004; 66(4): 1578–1588.
  • Tumlin J, Wali R, Williams W, et al. Efficacy and safety of renal tubule cell therapy for acute renal failure. J Am Soc Nephrol. 2008; 19(5): 1034–1040.
  • Kaneider NC, Leger AJ, Kuliopulos A. Therapeutic targeting of molecules involved in leukocyte-endothelial cell interactions. FEBSJ. 2006; 273(19): 4416–4424.
  • Maroszynska I, Fiedor P. Leukocytes and endothelium interaction as rate limiting step in the inflammatory response and a key factor in the ischemia-reperfusion injury. Ann Transplant. 2000; 5(4):5–11.
  • Ding F, Song JH, Lou L, et al. Novel selective cytopheretic inhibitory device (SCD) inhibits circulating leukocyte activation and ameliorates multiorgan dysfunction in a porcine model of septic shock. J Am Soc Nephrol. 2008; 19:458A.
  • Humes HD, Buffington DA. Selected cytopheresis device and related methods thereof. U.S. Patent WO2009/02981. Published June 4, 2009.
  • Humes HD, Sobota JT, Ding F, Song JH. A selective cytopheretic inhibitory device (SCD) to treat the immunologic dysregulation of acute and chronic renal failure. Blood Purif. In press.
  • Waikar SS, Liu KD, Chertow GM. Diagnosis, epidemiology and outcomes of acute kidney injury. Clin J Am Soc Nephrol. 2008; 3(3):844–861.
  • Imai E, Iwatani H. The continuing story of renal repair with stem cells. J Am Soc Nephrol. 2007; 18(9): 2423–2424.
  • Ding F, Humes HD. Acute Renal Failure. In: Malluche HH, ed. Clinical Nephrology, Dialysis and Transplantation. 2nd ed. Rockledge, FL; Dustri-Verlag; 2009.
  • Song JH, Humes HD. Renal cell therapy and beyond. Semin Dial. In press.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.